malinplc.com
Open in
urlscan Pro
79.170.244.67
Public Scan
URL:
http://malinplc.com/
Submission: On October 30 via manual from US — Scanned from DE
Submission: On October 30 via manual from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
*
About Us
*
Our Story
*
Leadership & Governance
*
Businesses
*
Investors
*
Investor Centre
*
Reports & Presentations
*
Share Price Information
*
News
*
Shareholder Centre
*
Events Calendar
*
Analyst & IR Contacts
*
Tender Offer – March 2023
*
Tender Offer – December 2021
*
Media
*
About Us
*
Our Story
*
Leadership & Governance
*
Businesses
*
Investors
*
Investor Centre
*
Reports & Presentations
*
Share Price Information
*
News
*
Shareholder Centre
*
Events Calendar
*
Analyst & IR Contacts
*
Tender Offer – March 2023
*
Tender Offer – December 2021
*
Media
MALIN IS A PUBLICLY LISTED COMPANY INVESTING IN HIGHLY INNOVATIVE LIFE SCIENCES
COMPANIES.
WE FOCUS ON ONCOLOGY, IMMUNOLOGY AND GENETIC DISEASES WHERE WE BELIEVE
INNOVATIVE LIFE SCIENCE AND HEALTHCARE TECHNOLOGIES WILL DELIVER TRANSFORMATIVE
TREATMENTS FOR PATIENTS.
Discover Our Story
Graphics
OUR PURPOSE IS TO DELIVER SIGNIFICANT RETURNS FOR SHAREHOLDERS AND
TRANSFORMATIVE OUTCOMES FOR PATIENTS THROUGH THE APPLICATION OF LONG-TERM
CAPITAL AND STRATEGIC SUPPORT TO OUR INVESTEE COMPANIES TO ENABLE THEM TO REACH
THEIR VALUE POTENTIAL.
MALIN ASSETS
--------------------------------------------------------------------------------
Malin Businesses
LATEST NEWS
--------------------------------------------------------------------------------
Investee Company News
Malin RNS Announcements
02 Aug 2023
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support
Continued Advancement of Clinical-Stage Bladder Cancer Pipeline
27 Jun 2023
Kymab successor company, Sanofi, announces positive topline Phase 2b data in
atopic dermatitis for amlitelimab (KY1005)
15 Nov 2022
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance
Clinical-Stage Urologic Oncology Pipeline
28 Apr 2022
FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and
Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic
Yeast Infection)
Fri, 27 Oct 2023
Director/PDMR Shareholding
Fri, 27 Oct 2023
Board Changes
Fri, 15 Sep 2023
Holding(s) in Company
Wed, 06 Sep 2023
Interim Results 2023
More News>
QUICK LINKS
The Malin Story
Reports & Presentations
News
Privacy Statement
Cookie Policy
COMPANY NEWS ALERTS
Sign up to receive the latest RNS and important company news
Sign Up
GENERAL CONTACT
T: +353 (0)1 901 5700
info@malinplc.com
Malin Corporation PLC
The Lennox Building
South Richmond Street
Dublin 2
D02 FK02
Ireland
> Media Contacts
KEEP IN TOUCH